This recombinant disintegrin antagonizes integrins alpha-IIb/beta-3 (ITGA2B/ITGB3) and alpha-V/beta-3 (ITGAV/ITGB3). On ITGA2B/ITGB3, it interferes with the outside/-in phosphorylation of the focal adhesion kinase (PTK2 / FAK) downstream of the integrin. It strongly inhibits platelet aggregation induced by ADP, thrombin, and collagen, abolishes and reverses dynamic platelet recruitment to immobilized fibrinogen. In vivo, it induces a dramatic increase in the tail bleeding time, and has a strong antithrombotic activity (PubMed:18508682). On ITGAV/ITGB3, it inhibits the adhesion of ITGAV/ITGB3-expressing human microvascular endothelial cell line and murine melanoma cell line to vitronectin (IC(50) = 555 nM and 225 nM, respectively), and transiently inhibits their proliferation without direct cell toxicity. In vivo, it potently inhibits angiogenesis and metastasis (PubMed:17952617), probably due to its capability to strongly inhibit the expression of VEGF and its receptors in endothelial cells (PubMed:22561350). It also inhibits tumor cell migration in vitro (PubMed:22069567). Monomer. Expressed by the venom gland. Is derived from the P-II subfamily of the venom metalloproteinase (M12B) family. The interaction between the disintegrin and the integrin ITGAV/ITGB3 is inhibited by EDTA, indicating a cation sensitive binding. The disintegrin belongs to the medium disintegrin subfamily. Belongs to the venom metalloproteinase (M12B) family. P-II subfamily. P-IIa sub-subfamily.